Kantarjian HM, Cortes JE, Kim D-W, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123(9):1309-1318.

On page 1314 in the 27 February 2014 issue, there is an error in the text. In the first sentence of the fourth paragraph in the “Characteristics and management of individual toxicities” section, “ADV” should have read, “myocardial infarction.” The sentence reads, “The collective incidence of cardiac-related TEAEs (combined analysis of MedDRA system organ class Cardiac Disorders and Investigations [cardiac and vascular terms]) was relatively low (18% of patients experienced any cardiac event, of whom most presented with prior or ongoing cardiac disorders at screening), with most patients (10%) experiencing maximum grade 1 or 2 events, 5% maximum grade 3 events, 2% maximum grade 4 events, and 1% grade 5 events (including death due to ADV [n = 3], congestive cardiac failure [n = 2], and cardiac failure and coronary artery disease [n = 1 each]).” The sentence should have read, “The collective incidence of cardiac-related TEAEs (combined analysis of MedDRA system organ class Cardiac Disorders and Investigations [cardiac and vascular terms]) was relatively low (18% of patients experienced any cardiac event, of whom most presented with prior or ongoing cardiac disorders at screening), with most patients (10%) experiencing maximum grade 1 or 2 events, 5% maximum grade 3 events, 2% maximum grade 4 events, and 1% grade 5 events (including death due to myocardial infarction [n = 3], congestive cardiac failure [n = 2], and cardiac failure and coronary artery disease [n = 1 each]).”

The error has been corrected in the online version, which now differs from the print version.